REVERSAL OF INSULIN-DEPENDENT DIABETES BY ISLET-PRODUCING STEM CELLS, ISLET PROGENITOR CELLS AND ISLET-LIKE STRUCTURES

• US 20080274090A1
• Filed: 01/25/2008
• Published: 11/06/2008
• Est. Priority Date: 09/27/1999
• Status: Abandoned Application

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Inventors: Peck, Ammon B., Cornelius, Janet G., Ramiya, Vijayakumar K.
• Application Number:
  US12/020,265
• Publication Number:
  US 20080274090A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2035/126 Immunoprotecting barriers, e.g. jackets, diffusion chambers
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2500/84 from mammals
• CPC Class Codes: C12N 5/0677 Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Abstract

The subject invention concerns new methods which make it possible, for the first time, to grow functional islet-producing stem cells (IPSCs), islet progenitor cells (IPCs) and IPC-derived islets (IdIs) in in vitro cultures. The subject invention also concerns the use of the in vitro grown IPSCs, IPCs and/or IdIs for implantation into a mammal for in vivo therapy of diabetes. The subject invention further concerns a process of using the implanted cells for growing a pancreas-like structure in vivo that has the same functional, morphological and histological characteristics as those observed in normal pancreatic endocrine tissue. The ability to grow these cells in vitro and pancreas-like structures in vivo opens up important new avenues for research and therapy relating to diabetes.

Claims

1. A method for growing islet producing stem cells (IPSCs), islet progenitor cells (IPCs) and IPC-derived islets (IdIs) comprising the steps of

a) culturing pancreatic cells from a mammalian species in vitro in a basal medium comprising serum less than about 0.5%, and glucose less than about 1 mM, undisturbed for at least 3 weeks, whereby an epithelial monolayer containing IPSCs is produced, and

b) initiating cellular differentiation, whereby IPCs and IdIs are produced.

15. A method for analyzing the differentiation of pancreatic stem cells which comprises culturing in vitro the IPSC and ductal epithelium composition of claim 1(a).

16. The method of claim 15 further comprising the step of inducing said IPSCs to initiate differentiation into IPCs and IdIs, whereby stages of differentiation are identified.

17. The method of claim 16 further comprising the step of identifying mRNA or protein markers specific to a stage of differentiation.

18. The method of claim 17 wherein the markers are expressed on the cell surface, are secreted or are intracellular.

2. An in vitro produced IPC-derived islet (IdI) comprising β

cells and either α

or PP cells, wherein said β

cells are located in the center of the IdI, said α

or PP cells are located in an outer cortex of the IdI, and proliferating and undifferentiated cells are located in an inner cortex of the IdI, wherein about 20 to 25% of the total cells of said IdI are β

cells.

5. A method of treating pancreatic disease or producing a pancreas-like structure in a mammal which comprises implanting the IdI of claim 2 or 3 into a tissue of the mammal.

6. The method of claim 5 wherein the IdI is encapsulated in an insulin, glucagon and somatostatin permeable capsule.

7. The method of claim 6 wherein the capsule is hyaluronic acid.

8. The method of claim 5 wherein the IPSCs from which the IdIs arise, originate from an individual into whom the IdI is implanted.

9. The method of claim 5 wherein the pancreatic disease is insulin-dependent diabetes.

3. An IdI comprising β

cells located in the center of the IdI, α

or PP cells located in an outer cortex of the IdI, and proliferating and undifferentiated cells located in an inner cortex of the IdI, wherein about 20 to 25% of the total cells of said IdI are β

cells, produced according to a method comprising the steps of;

a) culturing pancreatic cells from a mammalian species in vitro in a basal medium comprising serum less than about 0.5%, and glucose less than about 1 mM, undisturbed for at least 3 weeks, whereby an epithelial monolayer containing IPSCs is produced, and

b) initiating cellular differentiation, whereby IPCs and IdIs are produced.

4. The IdI of claim 3 wherein said IdI is human.

10. A method of treating pancreatic disease or producing a pancreas-like structure in a mammal which comprises the steps of

a) culturing pancreatic cells from a mammalian species in vitro under conditions that are favorable to the survival of IPSCs and ductal epithelial cells, and substantially lethal to differentiated cells, whereby a ductal epithelial monolayer containing IPSCs is produced,

b) initiating cellular differentiation, whereby IPCs and IdIs are produced,

c) implanting in a mammal a composition comprising said IdIs and optionally cells or tissue selected from the group consisting of said ductal epithelium, IPSCs, and IPCs and any combination thereof, whereby a pancreas-like structure and islet hormones are produced, providing for the treatment of the pancreatic disease.

11. The method of claim 10 wherein said composition is encapsulated before said implantation step.

12. The method of claim 10 wherein said implantation step comprises implanting into the mammal'"'"'s pancreatic tissue.

13. The method of claim 10 wherein said implantation step comprises implanting into a subcutaneous pocket of the mammal.

14. The method of claim 10 wherein said implantation step comprises implanting beneath a kidney capsule in the mammal.

19. A method for long-term propagation of IPSCs which comprises serially transferring a cellular composition comprising IdIs and optionally material selected from the group consisting of ductal epithelium, IPSCs, IPCs and any combination thereof.

20. The method of claim 19 wherein said serial transfer involves the transfer of IdIs and IPSCs.

21. A method for inducing neovascularization in a pancreatic implant in a mammal comprising transplanting into said mammal the pancreatic implant comprising IdIs and optionally cells or tissue selected from the group consisting of IPSCs and IPCs, whereby vascularization is induced or enhanced.

22. The method of claim 21 wherein the implanted tissue is only IdIs.

23. A structure consisting essentially of a pancreas-like structure produced by implantation of IdIs and optionally cells or tissues selected from the group consisting of IPSCs and IPCs, and comprising at least 50% by weight of endocrine tissue.

24. The pancreas-like structure of claim 23 wherein said structure comprises endocrine cells arranged in IdIs or anatomically similar structures.